5 :: KDA, Korean Diabetes Association ::
string(8) "resource"
Subject    :    [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Writer KDA
Date 2019-06-28 17:21:23 Hit 2,069
LINK URL https://e-dmj.org/DOIx.php?id=10.4093/dmj.2018.0051 (Click 47)
Diabetes Metab J. 2019 Jun;43(3):276-286. English.
Published online Dec 07, 2018.  https://doi.org/10.4093/dmj.2018.0051 
Copyright © 2019 Korean Diabetes Association
   
Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Tae Jung Oh,1 Jae Myung Yu,2 Kyung Wan Min,3 Hyun Shik Son,4 Moon Kyu Lee,5 Kun Ho Yoon,4Young Duk Song,6 Joong Yeol Park,7 In Kyung Jeong,8 Bong Soo Cha,9 Yong Seong Kim,10 Sei Hyun Baik,11 In Joo Kim,12 Doo Man Kim,13 Sung Rae Kim,4 Kwan Woo Lee,14 Jeong Hyung Park,15 In Kyu Lee,16 Tae Sun Park,17 Sung Hee Choi,1 and Sung Woo Park18
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
2Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
3Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
4Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
5Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
6Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
7Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
8Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
9Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
10Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
11Diabetes Center, Endocrinology and Metabolism, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
12Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
13Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
14Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
15Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
16Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
17Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.
18Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: Sung Hee Choi. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea. Email: drshchoi@snu.ac.kr Corresponding author: Sung Woo Park. Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Email: endoswpark@gmail.com 
 
Received March 23, 2018; Accepted June 22, 2018.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Background

Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus.

Methods

A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24.

Results

The reduction in the levels of HbA1c was −1.62%±0.07% in the vogmet group and −1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of <6.5% (P=0.002) or <7% (P=0.039). Glycemic variability was also significantly improved with vogmet treatment, estimated by M-values (P=0.004). Gastrointestinal adverse events and hypoglycemia (%) were numerically lower in the vogmet-treated group. Moreover, a significant weight loss was observed with vogmet treatment compared with metformin (−1.63 kg vs. −0.86 kg, P=0.039).

Conclusion

Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia.

   
Keywords:
Diabetes mellitus, type 2MetforminVoglibose
 

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iro... 2019-10-10 842
Notice : [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrom... 2019-10-10 849
Notice : [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabo... 2019-10-10 829
Notice : [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Aci... 2019-10-10 837
Notice : [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in ... 2019-10-10 826
Notice : [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal o... 2019-10-10 795
Notice : [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes Mellitus in A Chinese Population: A Nested Case-Control Study [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes ... 2019-10-10 778
Notice : [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011) [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuri... 2019-10-10 809
Notice : [2019 Aug;43(4)] Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies [2019 Aug;43(4)] Association between Serum Selenium Level and the Pr... 2019-10-10 789
Notice : [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Gl... 2019-10-10 781
Notice : [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with... 2019-10-10 796
Notice : [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovasc... 2019-10-10 781
Notice : [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabet... 2019-10-10 808
Notice : [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes ... 2019-10-10 790
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 2,150
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 2,308
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 2,132
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 2,166
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 2,093
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 2,536
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 2,069
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 2,076
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 2,325
252 [2015 Oct;39(5)] Relationship between Biological Markers, Metabolic ... 2015-12-08 6,367
251 [2015 Oct;39(5)] Serum Total Bilirubin Levels Provide Additive Risk ... 2015-12-08 6,360
250 [2015 Dec;39(6)] Insulin Initiation in Insulin-Naïve Korean Type 2... 2016-01-07 6,321
249 [2015 Dec;39(6)] The Usefulness of the Glycosylated Hemoglobin Level... 2016-01-07 6,281
248 [2015 Oct;39(5)] Increased Epicardial Adipose Tissue Thickness in Ty... 2015-12-08 6,173
247 [2016 Jun;40(3)] Renoprotective Effect of Gemigliptin, a Dipeptidyl ... 2016-07-05 6,135
246 [2015 Oct;39(5)] Dipeptidyl Peptidase 4 Inhibitors and the Risk of C... 2015-12-08 6,120
245 [2015 Oct;39(5)] Interaction between Glucose and Lipid Metabolism: M... 2015-12-08 6,113
244 [2016 Jun;40(3)] Effects of Rebamipide on Gastrointestinal Symptoms ... 2016-07-05 6,061
243 [2015 Dec;39(6)] Morphologic Changes in Autonomic Nerves in Diabetic... 2016-01-07 6,052

목록

Gets the previous 5 pages.   Go to previous page.  1   2   3   4   [5]     Go to next page. Gets the next  5 pages.